Countries like Spain have used 'most-favored-nation' drug pricing for decades. While it may reduce the cost of drugs, it will ...
Chinese pharmaceutical companies signed more than 150 external licensing agreements over innovative drugs in 2025, for a ...
In early December, the 2025 updates of China’s NRDL were finalised with a total of 114 drugs, including Western drugs and ...
The sheer growth of small biotechs and mid‑sized pharma companies entering the field has reshaped expectations of Contract ...
The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...
The revised EU pharmaceutical policy maintains eight-year data protection but reduces market protection to one year, extendable to three years under certain conditions. Orphan drug exclusivity is ...
In the rapidly evolving field of pharmaceuticals, China's role as a hub for innovative drug development continues to expand, particularly in its outbound strategies. As we approach the end of 2025, ...
AI emerged as a key differentiator in accelerating development timelines and enhancing clinical operations. Decentralized ...
In an age when antibiotic resistance poses a severe threat to global health, a new study sheds light on the often-overlooked hurdles of drug commercialization. Soaring costs associated with bringing ...
A survey has found that China, which is rapidly growing in the bio sector including the discovery of new drug candidates, is set to rise to become one of the world’s top three innovative drug markets.
An ad hoc committee will plan and host a 1.5-day public workshop to facilitate discussion focused on the translation of federal investments in biomedical science to innovation in drug development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback